Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Ancient Rome: A genetic crossroads of Europe and the Mediterranean.

Antonio ML, Gao Z, Moots HM, Lucci M, Candilio F, Sawyer S, Oberreiter V, Calderon D, Devitofranceschi K, Aikens RC, Aneli S, Bartoli F, Bedini A, Cheronet O, Cotter DJ, Fernandes DM, Gasperetti G, Grifoni R, Guidi A, La Pastina F, Loreti E, Manacorda D, Matullo G, Morretta S, Nava A, Fiocchi Nicolai V, Nomi F, Pavolini C, Pentiricci M, Pergola P, Piranomonte M, Schmidt R, Spinola G, Sperduti A, Rubini M, Bondioli L, Coppa A, Pinhasi R, Pritchard JK.

Science. 2019 Nov 8;366(6466):708-714. doi: 10.1126/science.aay6826.

PMID:
31699931
2.

Genetic Diversity on the Human X Chromosome Does Not Support a Strict Pseudoautosomal Boundary.

Cotter DJ, Brotman SM, Wilson Sayres MA.

Genetics. 2016 May;203(1):485-92. doi: 10.1534/genetics.114.172692. Epub 2016 Mar 23.

3.

Predicting Early Death Among Elderly Dialysis Patients: Development and Validation of a Risk Score to Assist Shared Decision Making for Dialysis Initiation.

Thamer M, Kaufman JS, Zhang Y, Zhang Q, Cotter DJ, Bang H.

Am J Kidney Dis. 2015 Dec;66(6):1024-32. doi: 10.1053/j.ajkd.2015.05.014. Epub 2015 Jun 26.

4.

Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.

Thamer M, Zhang Y, Kshirsagar O, Cotter DJ, Kaufman JS.

Am J Kidney Dis. 2014 Nov;64(5):706-13. doi: 10.1053/j.ajkd.2014.05.013. Epub 2014 Jul 8.

5.

Dialysis chains and placement on the waiting list for a cadaveric kidney transplant.

Zhang Y, Thamer M, Kshirsagar O, Cotter DJ, Schlesinger MJ.

Transplantation. 2014 Sep 15;98(5):543-51. doi: 10.1097/TP.0000000000000106.

PMID:
24798304
6.

Organizational status of dialysis facilities and patient outcome: does higher injectable medication use mediate increased mortality?

Zhang Y, Thamer M, Kshirsagar O, Cotter DJ.

Health Serv Res. 2013 Jun;48(3):949-71. doi: 10.1111/1475-6773.12019. Epub 2012 Dec 6.

7.

High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes.

Zhang Y, Thamer M, Kaufman JS, Cotter DJ, HernĂ¡n MA.

Kidney Int. 2011 Sep;80(6):663-9. doi: 10.1038/ki.2011.188. Epub 2011 Jun 22.

8.

The effect of dialysis chains on mortality among patients receiving hemodialysis.

Zhang Y, Cotter DJ, Thamer M.

Health Serv Res. 2011 Jun;46(3):747-67. doi: 10.1111/j.1475-6773.2010.01219.x. Epub 2010 Dec 9.

9.

Reevaluating erythropoiesis-stimulating agents.

Cotter DJ.

N Engl J Med. 2010 May 6;362(18):1743; author reply 1743-4. No abstract available.

PMID:
20449881
10.

Relative mortality and epoetin alpha dose in hemodialysis patients.

Cotter DJ, Thamer M, Zhang Y.

Am J Kidney Dis. 2008 May;51(5):865; author reply 865-6. doi: 10.1053/j.ajkd.2007.12.045. No abstract available.

PMID:
18436099
11.

Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.

Thamer M, Zhang Y, Kaufman J, Stefanik K, Cotter DJ.

Am J Kidney Dis. 2006 Jul;48(1):77-87.

PMID:
16797389
12.

Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients.

Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J.

J Clin Epidemiol. 2004 Oct;57(10):1086-95.

PMID:
15528060
13.

Epoetin requirements predict mortality in hemodialysis patients.

Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ.

Am J Kidney Dis. 2004 Nov;44(5):866-76.

PMID:
15492953
14.

Challenges in establishing a clinically and scientifically robust epoetin policy.

Cotter DJ.

Clin Nephrol. 2004 Jul;62(1):69-70. No abstract available.

PMID:
15267018
15.

Does dose matter?

Zhang Y, Thamer M, Stefanik K, Cotter DJ.

Nephrol Dial Transplant. 2004 Jun;19(6):1658; author reply 1658-9. No abstract available.

PMID:
15150368
16.

Improved survival with higher hematocrits: where is the evidence?

Cotter DJ, Stefanik K, Zhang Y, Thamer M.

Semin Dial. 2004 May-Jun;17(3):181-3.

PMID:
15144538
17.

Is the evidence for high hematocrit targets valid?

Cotter DJ.

Am J Kidney Dis. 2003 Feb;41(2):520; author reply 521. No abstract available.

PMID:
12552521
18.

Technology Assessment at the National Level in the US.

Cotter DJ, Perry S, Thamer M.

Surg Technol Int. 1999;8:45-8.

PMID:
12451508
19.

Use of clinical guidelines for treatment of anemia among hemodialysis patients.

Thamer M, Richard CM, Klinkmann J, Ivanovich P, Lang G, Cotter DJ.

Artif Organs. 2000 Feb;24(2):91-4.

PMID:
10718760
20.

Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.

Cotter DJ, Thamer M, Kimmel PL, Sadler JH.

Kidney Int. 1998 Dec;54(6):2129-39.

21.

The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.

Thamer M, Richard C, Ray NF, Greer JW, Cotter DJ, Pearson BC.

Am J Kidney Dis. 1996 Aug;28(2):235-49.

PMID:
8768919
22.

Excluded from universal coverage: ESRD patients not covered by Medicare.

Thamer M, Ray NF, Richard C, Greer JW, Pearson BC, Cotter DJ.

Health Care Financ Rev. 1995 Winter;17(2):123-46.

23.

Government's impact on medical technologies.

Cotter DJ.

Healthc Forum J. 1989 Sep-Oct;32(5):26, 28-9. No abstract available.

PMID:
10303840
24.
25.
26.

Ultrafiltration of molecules through deposited protein layers.

Dorson WJ, Cotter DJ, Pizziconi VB.

Trans Am Soc Artif Intern Organs. 1975;21:132-7.

PMID:
1145986
27.

Initial trials of a molecular separation artificial kidney.

Dorson WJ Jr, Pizziconi VB, Voorhees ME, Calkins JM, Christianson HB, Cotter DJ, Fargotstein R, Markovitz M, Monty DE Jr, Tomisaka DM.

Trans Am Soc Artif Intern Organs. 1973;19:109-18. No abstract available.

PMID:
4722726

Supplemental Content

Loading ...
Support Center